Prof Pierosandro Tagliaferri, MD
Oncology — Magna Graecia University, Italy
Pierosandro Tagliaferri
LeadR Profile
Oncology
Subspecialties: Hematology - Pharmacy - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1987 - 2026
Number : 406
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Reply to the Letter by Mazzitelli M. et al. Regarding "Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase". hematologic neoplasms, neoplasms, covid-19, pandemics | Cancer Med | 2026 | 0 |
| Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis. lymphoma, follicular, hematology, antibodies, lymphoma, rituximab, network meta-analysis, therapeutics, antibodies, bispecific | Br J Haematol | 2026 | 2 |
| CT-based radiomics as a non-invasive virtual biopsy for high PD-L1 expression prediction in non-small cell lung cancer. cells, lung, neoplasms, carcinoma, non-small-cell lung, biopsy, lung neoplasms, small cell lung carcinoma | Cancer Imaging | 2026 | 0 |
| HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study. genes, epidermal growth factor, growth, cetuximab, genes, erbb-2, neoplasms, biomarkers, receptors, growth factor, therapeutics, colorectal neoplasms, liquid biopsy, mutation | ESMO Gastrointest Oncol | 2026 | 0 |
| The role of the molecular tumor board: learnings from the ROME trial. pharmaceutical preparations, neoplasms, therapeutics | NPJ Precis Oncol | 2026 | 0 |
Clinical Studies 12
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A clinical study of sac TMT in people with breast cancer (MK 2870 032) 2024-520190-12-00 — triple negative breast neoplasms, safety, breast neoplasms, paclitaxel, neoplasms, drug therapy, respect, hormones, breast, neoadjuvant therapy, therapeutics, carboplatin, chemotherapy | Phase 3 | Recruiting | 2025 |
| CAPRI 3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected metastatic colorectal cancer patients 2024-519322-20-00 — cetuximab, neoplasms, drug therapy, therapeutics, colorectal neoplasms, chemotherapy | Phase 3 | Recruiting | 2025 |
| Phase III study in mCRC patients with RAS BRAF wild type tissue and RAS BRAF mutated in LIquid BIopsy to compare in first line therapy FOLFIRI plus CetuxiMAb or BevacizumaB 2024-517863-22-00 — cetuximab, genes, ras, bevacizumab, biopsy, drug therapy, diagnosis, therapeutics, tissues, liquid biopsy, chemotherapy | Phase 3 | Recruiting | 2024 |
| Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first line treatment of patients with unresectable left sided RAS B RAF wild type metastatic colorectal cancer (IMPROVE 2 trial) 2023-509551-14-00 — genes, ras, neoplasms, panitumumab, therapeutics, colorectal neoplasms | Phase 3 | Recruiting | 2024 |
| ROMANCE Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer NCT07381764 — vascular endothelial growth factor a, circulating tumor dna, cetuximab, trifluridine, pharmaceutical preparations, antineoplastic agents, neoplasms, drug combinations, bevacizumab, drug therapy, body weight, antibodies, monoclonal, therapeutics, colorectal neoplasms, irinotecan, chemotherapy | Phase 2 | Recruiting | 2026 |
LeadR Networks
Main global connection map